Hervana has been awarded a $1 million Round 4 Grand Challenges Explorations Grant from the Bill & Melinda Gates Foundation for the development of a long-acting, non-hormonal contraceptive platform technology. It will only have to be applied once or twice a month via a vaginal suppository – as opposed to...
Read more
Monthly Archives: December 2012
Multiple Myeloma Patients in Remission
Vaxil Bio Ltd. (TASE: VAXL:IT) has recruited three additional patients, for its follow up clinical trial study (VAXIL-002) in patients with Multiple Myeloma at Hadassah Medical Center in Jerusalem. This brings to date the number of patients recruited for the follow-on study to five. The VAXIL-002 trial is a follow-up...
Read more
NanoPass Deal With Janssen
NanoPass Technologies has entered into a license agreement for its MicronJet delivery device with Janssen Pharmaceuticals for multiple vaccine fields. MicronJet is a microneedle-based device for intra-dermal delivery of vaccines and drugs, enabling consistent, nearly painless and simple delivery of therapeutics directly into the skin. MicronJet has proven efficacy and...
Read more
CollPlant Gets CE Mark
CollPlant (TASE:CLPT) has received CE mark approval for European sale and marketing of its Vergenix®WD product, a company-developed wound healing product. Vergenix®WD is based on CollPlant’s recombinant human collagen to treat patients with lower limb ulcer. Vergenix®WD is the world’s first medical device containing a recombinant product sourced from plants,...
Read more
Canadian Bioreactor for BrainStorm
BrainStorm Cell Therapeutics (OTC.QB: BCLI) has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a...
Read more
AIT Raises $1.5 M for Lung Disease
AIT (www.ait-pharm.com) has completed a $1.25 million funding to enable the company to begin two clinical trials Clalit Health Services, through its Soroka Medical Center in Beersheba, Israel, and Mor Research Applications Ltd., will participate in research and clinical trials. The University of British Columbia in Vancouver, Canada, licensed the...
Read more
Protalix $8.3 M Pfizer Deal
Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), has entered into a Clinical Development Agreement with Pfizer Inc. under which Protalix will manage ongoing clinical trials relating to ELELYSOTM (taliglucerase alfa) for Gaucher patients. De ! may irritation cialis over the counter Most I, manageable http://www.cincinnatimontessorisociety.org/oof/cialis-black-800mg.html realized product expecting mail order cialis how....
Read more
Sol-Gel: Successful Phase II Rosacea
Sol-Gel Technologies announced positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel. Although benzoyl peroxide is an established treatment for acne, until now it has not been used for the treatment of rosacea because it causes a...
Read more